About Replay
Replay is a Healthcare company based in San Diego (United States) founded in 2021 by Ron Weiss, David Knipe, and Lachlan MacKinnon, and was acquired by LEO Pharma in April 2026. It operates as a genomic reprogramming platforms for DNA writing and delivery are offered. It operates on a HealthTech model. Replay has raised $55 million across 2 funding rounds from investors including LEO Pharma, KKR and Gates Foundation. The company has 13 employees. Its chief executive is Lachlan MacKinnon. Replay offers products and services including Big DNA Delivery. Its focus areas include Biotechnology and Gene Therapy. Its legal entity is Replay Holdings, Inc. Its competitors include BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
Replay is engaged in developing big DNA delivery solutions for treating monogenic and polygenic diseases through gene therapy. The company specializes in delivering 150kb DNA using HSV technology. Their efforts are centered in the biotechnology sector, aiming to address complex genetic disorders with innovative therapeutic approaches.
- Headquarters San Diego, United States
- Employees 13
- Founders Ron Weiss, David Knipe, Lachlan MacKinnon
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website replay.bio
- Social LinkedIn X
- Acquired by LEO Pharma (Apr 2026)
- Legal Name Replay Holdings, Inc.
- Total Equity Funding$55M (USD)
in 2 rounds
- Latest Funding Round$1.5M (USD), Grant
Nov 2022
- InvestorsLEO Pharma
& 8 more
- Employee Count13
- Acquired byLEO Pharma
(Apr 2026)
Products & Services of Replay
Replay offers a comprehensive portfolio of products and services, including Big DNA Delivery.
Big DNA delivery is developed for disease treatment.
Funding Insights of Replay
Replay has successfully raised a total of $55M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $1.5 million completed in November 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $55M
- Total Rounds 2
- Last Round Grant — $1.5M
- First Round $55M
(Jul 2022)
- Investors Count 8
All 2 funding rounds of Replay with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2022 | $1.5M | Grant | – | – | |
| Jul 2022 | $55M | Seed | – | KKR, OMX Ventures |
9 investors in total: 9 institutional.
Investors in Replay
Replay has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include LEO Pharma, KKR and Gates Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multiple sectors are invested in by this private equity firm. | 1976 | kkr.com | New York, United States | |
Venture capital investments are made in transformative biotech companies by OMX Ventures. | – | omx.vc | Lincolnshire, USA | |
Early-stage startups are invested in by Artis Ventures. | – | av.co | San Francisco, United States | |
- | – | axialvc.com | - | |
Charitable foundation investments on poverty reduction and healthcare | 2000 | gatesfoundation.org | Seattle, United States | |
Offers fundamental equity investing and management for institutional clients since 1998. | 1998 | lansdownepartners.com | London, United Kingdom | |
Offers strategy consulting, market research, and data analytics in precision medicine. | 2009 | decibio.com | Los Angeles, United States | |
Mobile network services are provided in Switzerland by Salt Mobile. | 1999 | salt.ch | Renens, Switzerland | |
Developer of drugs for treating dermatology diseases | 1908 | leo-pharma.com | Copenhagen, Denmark |
Investor details for Replay
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Replay
14 people are tracked at Replay (5 in leadership, 1 in board & advisors, 8 in team); the tracked headcount is 13.
| Name | Role | Group |
|---|---|---|
Ron Weiss | Co-Founder | Leadership |
David Knipe | Co-Founder | Leadership |
Lachlan MacKinnon | Co-Founder & CEO | Leadership |
Maria Castner Miller | Senior Vice President and General Counsel | Leadership |
Amy Brunetto Phillips | Senior Director of Partnerships | Leadership |
Dame Carol | Scientific Advisor | Board & advisors |
Susan N Holley | Senior Scientist | Team |
Lei Zhang | Scientist | Team |
Cynthia Reyes | Scientist | Team |
HorngDer Ou | Principal Scientist | Team |
Gregory Cadwell | Associate Scientist | Team |
Jaimeson Veldhuizen | Scientist II | Team |
Huan Liu | Senior Scientist | Team |
Idania Marrero | Principal Scientist, Cellular Immunology | Team |
Complete people profiles for Replay
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Replay
4 dated milestones of Replay across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Replay is founded.
- Funding First funding round of $55.0M.
- Funding Latest funding round, Grant, of $1.5M.
- Exit Acquired by LEO Pharma.
Competitors of Replay
Replay has 9 listed competitors in our database, 9 of them funded. They include BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| atai.life | 2018 | Munich, Germany | $386.67M | – | A biopharmaceutical company accelerating innovative mental health treatments. | |
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. | |
| chimerix.com | 2002 | Durham, United Kingdom | $95.23M | 72 | Antiviral oral therapeutics are developed for infectious diseases and cancers. | |
| cariboubio.com | 2011 | Berkeley, United States | $156.55M | 92 | Provider of cell therapies to treat cancer and hematologic conditions |
Detailed competitors of Replay
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Replay
The website of Replay (replay.bio) receives about 3K visits a month.
- Monthly visits3K
▲ 24.8% vs previous month
Websites whose visitors overlap most with Replay. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
replaylakeview.com | replaylakeview.com | 100% | – | #4,596,856 | – |
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as Replay (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 562 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Replay
Complete news archive for Replay
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Replay
Replay was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Replay is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Lachlan MacKinnon is the current CEO of Replay. They have also founded this company.
Replay is a funded company, having raised a total of $55M across 2 funding rounds to date. The company's 1st funding round was a Seed of $55M, raised on Jul 2022.
Replay has 13 employees.
Replay is engaged in developing big DNA delivery solutions for treating monogenic and polygenic diseases through gene therapy. The company specializes in delivering 150kb DNA using HSV technology. Their efforts are centered in the biotechnology sector, aiming to address complex genetic disorders with innovative therapeutic approaches.
Replay's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Replay offers Big DNA Delivery.
Replay has 9 investors. Key investors include LEO Pharma, KKR, Gates Foundation, Salt Mobile, and OMX Ventures.
Replay operates through Replay Holdings, Inc..
Yes. Replay was acquired by LEO Pharma in April 2026.